PriceTargets.com logo

Inogen - INGN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.00
  • Forecasted Upside: -23.83%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.19 As of 10/22/2024 01:00 AM ET
▲ +0.09 (0.99%)

This chart shows the closing price for INGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INGN

Analyst Price Target is $7.00
▼ -23.83% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Inogen in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a -23.83% upside from the last price of $9.19.

This chart shows the closing price for INGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Inogen. This rating has held steady since January 2024, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/7/2024Needham & Company LLCReiterated RatingHold
5/8/2024Stifel NicolausBoost TargetHold ➝ Hold$6.00 ➝ $7.00
5/8/2024Needham & Company LLCReiterated RatingHold
4/9/2024Needham & Company LLCReiterated RatingHold
2/15/2024William BlairUpgradeMarket Perform ➝ Outperform
11/8/2023JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$8.00 ➝ $7.00
8/8/2023Stifel NicolausLower TargetHold ➝ Hold$15.00 ➝ $8.00
8/8/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$15.00 ➝ $8.00
7/13/2023Needham & Company LLCDowngradeBuy ➝ Hold
4/20/2023Needham & Company LLCReiterated RatingBuy$26.00
2/24/2023Needham & Company LLCLower TargetBuy$36.00 ➝ $26.00
1/17/2023William BlairDowngradeOutperform ➝ Market Perform
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$32.00 ➝ $22.00
11/2/2022Needham & Company LLCLower TargetBuy$45.00 ➝ $36.00
5/9/2022Stifel NicolausLower Target$40.00 ➝ $30.00
12/9/2021Needham & Company LLCUpgradeHold ➝ Buy$47.00
11/8/2021Stifel NicolausLower TargetHold$70.00 ➝ $40.00
11/5/2021Leerink PartnersLower TargetMarket Perform$72.00 ➝ $42.00
11/2/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$71.00 ➝ $45.00
8/8/2021Needham & Company LLCReiterated RatingHold
7/20/2021Leerink PartnersReiterated RatingMarket Perform
6/4/2021William BlairUpgradeMarket Perform ➝ Outperform
5/5/2021Leerink PartnersBoost TargetMarket Perform$67.00 ➝ $72.00
5/5/2021KeyCorpBoost TargetPositive ➝ Overweight$60.00 ➝ $75.00
2/25/2021Leerink PartnersBoost TargetMarket Perform$47.00 ➝ $54.00
12/14/2020KeyCorpUpgradeSector Weight ➝ Overweight$60.00
11/13/2020Needham & Company LLCReiterated RatingHold
8/5/2020Leerink PartnersLower TargetMarket Perform$42.00 ➝ $35.00
7/23/2020Needham & Company LLCDowngradeBuy ➝ Hold
6/10/2020William BlairDowngradeOutperform ➝ Market Perform
6/1/2020Leerink PartnersBoost TargetMarket Perform$42.00 ➝ $56.00
5/6/2020Leerink PartnersLower TargetMarket Perform$68.00 ➝ $56.00
5/6/2020Needham & Company LLCLower TargetBuy$80.00 ➝ $75.00
2/26/2020JPMorgan Chase & Co.Lower TargetUnderweight$60.00 ➝ $45.00
12/20/2019JPMorgan Chase & Co.Boost TargetUnderweight$47.50 ➝ $60.00
11/22/2019Needham & Company LLCReiterated RatingBuy$90.00
11/6/2019Needham & Company LLCUpgradeHold ➝ Buy$90.00
(Data available from 10/23/2019 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/26/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Inogen logo
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Read More

Today's Range

Now: $9.19
Low: $9.03
High: $9.28

50 Day Range

MA: $10.80
Low: $8.90
High: $12.98

52 Week Range

Now: $9.19
Low: $4.13
High: $13.33

Volume

123,375 shs

Average Volume

342,707 shs

Market Capitalization

$216.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Inogen?

The following equities research analysts have issued research reports on Inogen in the last twelve months: JPMorgan Chase & Co., Needham & Company LLC, Stifel Nicolaus, StockNews.com, and William Blair.
View the latest analyst ratings for INGN.

What is the current price target for Inogen?

2 Wall Street analysts have set twelve-month price targets for Inogen in the last year. Their average twelve-month price target is $7.00, suggesting a possible downside of 23.8%. JPMorgan Chase & Co. has the highest price target set, predicting INGN will reach $7.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $7.00 for Inogen in the next year.
View the latest price targets for INGN.

What is the current consensus analyst rating for Inogen?

Inogen currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INGN, but not buy more shares or sell existing shares.
View the latest ratings for INGN.

What other companies compete with Inogen?

Other companies that are similar to Inogen include Jin Medical International, Sanara MedTech, Lakeland Industries, Alpha Pro Tech and Nutriband. Learn More about companies similar to Inogen.

How do I contact Inogen's investor relations team?

Inogen's physical mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company's listed phone number is (805) 562-0500 and its investor relations email address is [email protected]. The official website for Inogen is www.inogen.com. Learn More about contacing Inogen investor relations.